English | 简体中文 | 繁體中文 | 한국어
Share:
Helén Tuvesson new CEO of Active Biotech AB from July 1, 2017

PRESS RELEASE

Lund - Active Biotech AB (Nasdaq Stockholm: ACTI) today announces that the Board has appointed the company's current CSO Helén Tuvesson as new CEO of Active Biotech AB. Helén Tuvesson will take up the position on July 1, 2017, replacing Tomas Leanderson, who has been the company's CEO since 2008.

Helén Tuvesson has a broad experience in drug development after more than 20 years in the pharmaceutical industry. Helén has held various senior positions in Active Biotech and since 2011 she has been responsible for the company's research and development.

"I am proud and glad that in Helén Tuvesson we have an internal candidate who can take responsibility as CEO, ensuring continuity and a controlled handover. Helén has been instrumental in the structural changes made in the company during 2016/2017 and has a solid industry experience. I am convinced that she has the qualities required to shape the company's future strategy and maximize its opportunities," says Mats Arnhög, Chairman of the Board.

"I would also like to thank Tomas Leanderson for his significant contribution to the company's business for a long period. Tomas Leanderson will be at the company's disposal during a transitional period," said Mats Arnhög.

"I am very happy and at the same time humbled for the confidence to lead Active Biotech further. I am well acquainted with the company's projects and its potential and look forward to developing the portfolio further and creating value for the company," says Helén Tuvesson.

Lund June 19, 2017
Active Biotech AB (publ)

For further information, please contact:
Mats Arnhög
Chairman of the Board
Tel +46 8 54503770
Mobil: +46 705 915096

Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/ inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Anyara, cancer immunotherapy, previously in clinical Phase 1-2/3 development in patients with pancreatic-, lung- or renal cancer. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00

This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 15.30 a.m. CET on June 19, 2017.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire

Copyright © Thomson Reuters 2018. All rights reserved.
Press Releases
Orion to sell its Orion Diagnostica division - Due to the transaction Orion updates its outlook  
Apr 21, 2018 00:30 ET
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/ palonosetron) in the United States  
Apr 20, 2018 21:33 ET
BOURBON: Positive progress in negotiations with lenders  
Apr 20, 2018 18:30 ET
Hubbell Incorporated Declares Regular Quarterly Dividend  
Apr 20, 2018 16:01 ET
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/ palonosetron) in the United States  
Apr 20, 2018 15:23 ET
Heineken Holding N.V. - Amendments to the Articles of Association  
Apr 20, 2018 15:18 ET
Lubrizol Presents Estane® TPU and Other Innovations for Consumer, Industrial, Footwear and Electronics Applications at Chinaplas 2018  
Apr 20, 2018 12:03 ET
Lipotec Active Ingredients Becomes Umbrella Brand  
Apr 19, 2018 23:43 ET
LEH PHARMA LTD.: Company Update  
Apr 18, 2018 19:34 ET
Tusk Therapeutics presents data on to its anti-CD25 programme at AACR Annual Meeting 2018  
Apr 18, 2018 19:33 ET
More News >>
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: